Loading
Double-hit lymphoma is a large B-cell lymphoma with rearrangements of two oncogenes (MYC plus BCL2 and/or BCL6), which behaves aggressively and often escapes R-CHOP.
Double-hit lymphoma is a large B-cell lymphoma carrying rearrangements of two oncogenes, MYC together with BCL2 and/or BCL6, which behaves aggressively and often escapes R-CHOP. The WHO 2022 classification names the MYC and BCL2 form high-grade B-cell lymphoma with MYC and BCL2 rearrangements (HGBL-DH-BCL2), while the MYC and BCL6 double hit has been reclassified as DLBCL not otherwise specified. It accounts for a small minority of DLBCL and is often treated with the more intensive DA-EPOCH-R regimen rather than R-CHOP. CAR-T outcomes in ZUMA-7 were similar to those in other large B-cell lymphomas, so the diagnosis does not exclude cellular therapy. Readers meet it on the DLBCL and HIV-associated lymphoma pages and through the BCL-2 target.
In plain words · A protein that stops cells from self-destructing. Venetoclax removes that protection and has transformed leukaemia treatment.
Showing the target this term concerns: BCL-2.
The evidence that made lisocabtagene maraleucel the CD19 CAR-T product most often chosen for older or frailer patients, because its severe cytokine release syndrome rate is a fraction of the other two products'.
R-CHOP remains the standard first-line regimen for diffuse large B-cell lymphoma. The trial is also the clearest lesson in the disease about adopting a regimen on single-arm data: dose-adjusted EPOCH-R had been used widely for a decade before this comparison existed.
Shares CNS prophylaxis in aggressive B-cell lymphoma, and the evidence against it, BCL6, Intrinsic apoptosis (BCL-2 family), MYC.
Shares Intrinsic apoptosis (BCL-2 family), MYC, MYC, BCL-2.
Shares BCL6, Intrinsic apoptosis (BCL-2 family), MYC, MYC.
Shares BCL6, MYC, BCL-2, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting.
Shares BCL6, Intrinsic apoptosis (BCL-2 family), MYC, BCL-2.
Shares MYC, Burkitt lymphoma, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Non-Hodgkin lymphoma (all types).
Shares BCL6, BCL-2, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Diffuse large B-cell lymphoma.
Shares Intrinsic apoptosis (BCL-2 family), BCL-2, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types).